-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Mount Sinai research team used a genomic network model to measure tumor aggressiveness -- distinguishing aggressive tumors from so-called "indolent" tumors that are often indistinguishable from chest CT scans -- and to identify those that inhibit Aurora kinase inhibition.
"Methods for diagnosing and treating early-stage lung adenocarcinoma are developing based on advances in the understanding of the biology and clinical activity of these tumors,
The research team used a genetically engineered mouse model to determine the role of aurora kinase in early disease progression
The researchers encourage further validation and clinical trials in human tumors
Researchers from Weill Cornell Medicine-NewYork-Presbyterian Hospital and Sema4, a patient-centric health intelligence company, participated in the study
Journal Reference :
Seungyeul Yoo, Abhilasha Sinha, Dawei Yang, Nasser K.